Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + SOX adjuvant therapy for stage III gastric or gastroesophageal junction adenocarcinoma
ChiCTR2100051682Phase 4Not yet recruiting
- Sponsor
- Second Affiliated Hospital of Shandong First Medical University
- Start
- Oct 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of camrelizumab, oxaliplatin and tegafur in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Second Affiliated Hospital of Shandong First Medical University. Primary endpoint: 3-year disease-free survival. Planned start Oct 2021; status: not yet recruiting.
02
Drugs
camrelizumaboxaliplatintegafur
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2100051682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100051682.